Some side effects and effcts on physical activity of second-generation antipsychotics: A study in children and adolescents

Arman, Soroor; Sadeghye, Tahere; Bidaki, Reza

Some side effects and effcts on physical activity of second-generation antipsychotics: A study in children and adolescents

Authors

¹ Department of Psychiatry, Isfahan University of Medical Sciences, Isfahan, Iran

² Shahid Sadoughi University of Medical Sciences, Yazd, Iran

³ Rafsanjan University of Medical Sciences, Rafsanjan, Iran

Abstract

Background: This study was designed to investigate the metabolic adverse effects (AEs) of second-generation antipsychotics (SGAs) and their relationship with physical activity and non-metabolic AE in children and adolescents.
Materials and Methods: After exclusion of patients with metabolic syndrome, 62 patients (34 children, 28 adolescents) of both genders who were candidates for SGA therapy were selected. Metabolic parameters included fasting blood glucose (FBG), triglyceride (TG), blood pressure (BP), and waist circumference (WC); non-metabolic AEs and physical activity were evaluated at baseline, 1 month, and 3 months after starting the treatment.
Results: Mean of post-treatment FBG and TG were significantly higher than the baseline values (P < 0.0001). Compared to the baseline value, significantly more patients developed abnormally high (AbH) FBG at the end point (P = 0.02). There was no significant difference in the frequency of patients with AbH-FBG either at the baseline or at the end point (P > 0.05). The frequency of patients with AbH-TG at the end point was not significantly higher than those with baseline AbH-TG (P = 0.10). Although no patient was obese at baseline, 11 (18%) patients developed abdominal obesity at the end point (P < 0.0001). There was no significant difference in the frequency of non-metabolic AE (P > 0.05). There was no significant correlation between metabolic and non-metabolic AE (P > 0.05). Frequency of inactive patients was significantly more than the baseline value (P-0.008), and abdominal obesity was significantly more prevalent in less active participants (P = 0.03).
Conclusion: The present study showed the AE of SGA on FBG and TG, but no effect on BP and WC. We also found that children are more prone to develop abnormally high FBG.

Keywords

References

1.	Arman S, Keypour M, Maracy MR, Attari A. Epidemiological study of youth mental health using strengths and difficulties questionnaire. Iran Red Crescent Med J 2012;14:371-5.
2.	Al-Jawadi AA, Abdul-Rhman S. Prevalence of childhood and early adolescence mental disorders among children attending primary health care centers in Mosul, Iraq: A cross-sectional study. BMC Public Health 2007;7:274.
3.	Harrison JN, Cluxton-Keller F, Gross D. Antipsychotic medication prescribing trends in children and adolescents. J Pediatr Health Care 2012;26:139-45.
4.	Findling RL, Steiner H, Weller EB. Use of antipsychotics in children and adolescents. J Clin Psychiatry 2005;66 Suppl 7:29-40.
5.	Vitiello B, Correll C, van Zwieten-Boot B, Zuddas A, Parellada M, Arango C. Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol 2009;19:629-35.
6.	Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006;63:679-85.
7.	Olfson M, Crystal S, Huang C, Gerhard T. Trends in antipsychotic drug use by very young, privately insured children. J Am Acad Child Adolesc Psychiatry 2010;49:13-23.
8.	Panagiotopoulos C, Ronsley R, Elbe D, Davidson J, Smith DH. First do no harm: Promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. J Can Acad Child Adolesc Psychiatry 2010;19:124-37.
9.	Rani F, Murray ML, Byrne PJ, Wong IC. Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 2008;121:1002-9.
10.	De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry 2011;26:144-58.
11.	Zuddas A, Zanni R, Usala T. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: A review of the randomized controlled studies. Eur Neuropsychopharmacol 2011;21:600-20.
12.	Alvarez-Jimenez M, Gonzalez-Blanch C, Crespo-Facorro B, Hetrick S, Rodriguez-Sanchez JM, Perez-Iglesias R, et al. Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: A systematic critical reappraisal. CNS Drugs 2008;22:547-62.
13.	Anderson GM, Scahill L, McCracken JT, McDougle CJ, Aman MG, Tierney E, et al. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry 2007;61:545-50.
14.	Cahn W, Ramlal D, Bruggeman R, de Haan L, Scheepers FE, van Soest MM, et al. Prevention and treatment of somatic complications arising from the use of antipsychotics. Tijdschr Psychiatr 2008;50:579-91.
15.	Correll CU. Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. Int Rev Psychiatry 2008;20:195-201.
16.	Correll CU, Penzner JB, Parikh UH, Mughal T, Javed T, Carbon M, et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am 2006;15:177-206.
17.	Correll CU, Sheridan EM, DelBello MP. Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: A comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord 2010;12:116-41.
18.	Van Gaal LF. Long-term health considerations in schizophrenia: Metabolic effects and the role of abdominal adiposity. Eur Neuropsychopharmacol 2006; 16 Suppl 3:S142-8.
19.	Merchan-Naranjo J, Tapia C, Bailon C, Moreno C, Baeza I, Calvo-Escalona R, et al. Secondary effects of antipsychotic treatment in naive or quasi-naive children and adolescents: Design of a follow-up protocol and baseline results. Rev Psiquiatr Salud Ment 2012;5:217-28.
20.	Martine A, Volkmar FR, Lewis S. Adolescence: Development of school age children. Child and Adolescent psychiatry. New York, London: Lippincott Williams and Wilkins Heals; 2007.
21.	Mancini MC. Metabolic syndrome in children and adolescents-criteria for diagnosis. Diabetol Metab Syndr 2009;1:20.
22.	Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003;35:1381-95.
23.	Amorim PR, de Faria RC, Byrne NM, Hills AP. Physical activity and nutritional status of children of low socioeconomic status. Two interrelated problems: Undernutrition and overweight. Asia Pac J Clin Nutr 2006;15:217-23.
24.	Liang YJ, Xi B, Song AQ, Liu JX, Mi J. Trends in general and abdominal obesity among Chinese children and adolescents 1993-2009. Pediatr Obes 2012;7:355-64.
25.	Sorof JM, Eissa MA, Bernard L, Portman RJ. O-29: High hypertension prevalence and the relationship of body mass index (BMI) to blood pressure in ethnic minority children. Am J Hypertens 2001;14:14.
26.	Redline S, Storfer-Isser A, Rosen CL, Johnson NL, Kirchner HL, Emancipator J, et al. Association between metabolic syndrome and sleep-disordered breathing in adolescents. Am J Respir Crit Care Med 2007;176:401-8.
27.	Croarkin PE, Emslie GJ, Mayes TL. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: A review of published cases. J Clin Psychiatry 2008;69:1157-65.
28.	Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009;166:152-63.
29.	Overbeek WA, de Vroede MA, Lahuis BE, Hillegers MH, de Graeff-Meeder ER. Antipsychotics and metabolic abnormalities in children and adolescents: A review of the literature and some recommendations. Tijdschr Psychiatr 2010;52:311-20.
30.	De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2012;8:114-26.
31.	Delbello MP, Correll CU, Carlson GA, Carlson HE, Kratochvil CJ. Pharmacological management of bipolar disorder in a youth with diabetes. J Am Acad Child Adolesc Psychiatry 2007;46:1375-9.
32.	Stigler KA, Potenza MN, Posey DJ, McDougle CJ. Weight gain associated with atypical antipsychotic use in children and adolescents: Prevalence, clinical relevance, and management. Paediatr Drugs 2004;6:33-44.
33.	Citrome LL. The increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents. Drugs Today (Barc) 2004;40:445-64.
34.	Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009;302:1765-73.
35.	Moreno C, Merchan-Naranjo J, Alvarez M, Baeza I, Alda JA, Martinez-Cantarero C, et al. Metabolic effects of second-generation antipsychotics in bipolar youth: Comparison with other psychotic and nonpsychotic diagnoses. Bipolar Disord 2010;12:172-84.
36.	Nicol G HD, Flavin K, Schweiger J, Hessler M, Hessler E, et al. Preliminary results of the MEAC study: Metabolic effects of antipsychotics in children. Schizophr Bull 2009;35:32.
37.	Alacqua M, Trifiro G, Arcoraci V, Germano E, Magazu A, Calarese T, et al. Use and tolerability of newer antipsychotics and antidepressants: A chart review in a paediatric setting. Pharm World Sci 2008;30:44-50.
38.	Stigler KA, Potenza MN, Posey DJ, McDougle CJ. Weight gain associated with atypical antipsychotic use in children and adolescents: Prevalence, clinical relevance, and management. Paediatr Drugs 2004;6:33-44.
39.	Aman MG, Arnold LE, McDougle CJ, Vitiello B, Scahill L, Davies M, et al. Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol 2005;15:869-84.
40.	Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002;159:1337-46.
41.	McGough JJ, Pataki CS, Suddath R. Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder. Expert Rev Neurother 2005;5:437-41.
42.	Correll CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: A systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry 2007;46:687-700.
43.	Panagiotopoulos C, Ronsley R, Kuzeljevic B, Davidson J. Waist circumference is a sensitive screening tool for assessment of metabolic syndrome risk in children treated with second-generation antipsychotics. Can J Psychiatry 2012;5734-44.
44.	Klingerman CM, Stipanovic ME, Bader M, Lynch CJ. Second-generation antipsychotics cause a rapid switch to fat oxidation that is required for survival in C57BL/6J mice. Schizophr Bull 2013 Jan 17.
45.	Albaugh VL, Judson JG, She P, Lang CH, Maresca KP, Joyal JL, et al. Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis. Mol Psychiatry 2011;16:569-81.
46.	Sampey CS, Follin SL. Second-generation antihistamines: The OTC debate. J Am Pharm Assoc (Wash) 2001;41:454-7.

Advanced Biomedical Research